At the European Society of Emergency Medicine Congress, UK-based Mundipharma announced positive results from various trials of its analgesic Penthrox (methoxyflurane) for pain relief.
The Mundipharma network of independent associated companies announced today that the first patient has been enrolled into a new study investigating the efficacy of Penthrox® ? (methoxyflurane, MEOF) in conscious, stable adult patients with moderate-to-severe trauma-related pain rescued from hostile, mountainous areas.1 The METEORA trial is a Phase IIIb, prospective, single-arm, multicentre trial in 200 adult patients with limb trauma who are rescued by the Helicopter Emergency Medical Service (HEMS) in Italy.1
Purdue Pharma (Canada) and Medical Developments International Limited (MDI), announce today that PENTHROX®, a low dose methoxyflurane, has been granted marketing authorization by Health Canada for the short-term relief of moderate to severe acute pain, associated with trauma or interventional medical procedures, in conscious adult patients1.